{{medical}}
{{Infobox drug
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 462089041
| IUPAC_name = ''N''-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-<br/>[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]<br/>quinazolin-4-amine
| image = Lapatinib.svg
| width = 275

<!--Clinical data-->
| tradename = Tykerb, Tyverb, others
| Drugs.com = {{drugs.com|monograph|lapatinib-ditosylate}}
| MedlinePlus = a607055
| licence_EU = yes
| DailyMedID = Lapatinib
| licence_US = Lapatinib
| pregnancy_AU = C
| pregnancy_US = N
| pregnancy_category =
| legal_AU = S4
| legal_CA = Rx-only
| legal_UK = POM
| legal_US = Rx-only
| legal_status = Rx-only
| routes_of_administration = [[Oral_administration|By mouth]] ([[Tablet_(pharmacy)|tablets]])
| ATC_prefix = L01
| ATC_suffix = EH01

<!--Pharmacokinetic data-->
| bioavailability = Variable, increased with food
| protein_bound = >99%
| metabolism = [[Liver|Liver]], mostly [[CYP3A|CYP3A]]-mediated (minor [[CYP2C19|2C19]] and [[CYP2C8|2C8]] involvement)
| elimination_half-life = 24 hours (repeated dosing), 14.2 hours (single dose)
| excretion = Mostly [[Feces|Feces]]

<!--Identifiers-->
| index2_label = as salt
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 231277-92-2
| CAS_number2_Ref = {{cascite|changed|??}}
| CAS_number2 = 388082-78-8
| CAS_supplemental = 
| PubChem = 208908
| IUPHAR_ligand = 5692
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01259
| DrugBank2_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank2 = DBSALT001785
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 181006
| ChemSpiderID2_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID2 = 9731817
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 0VUA21238F
| UNII2_Ref = {{fdacite|correct|FDA}}
| UNII2 = G873GX646R
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D08108
| KEGG2_Ref = {{keggcite|changed|kegg}}
| KEGG2 = D04024
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 49603
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 554
| ChEMBL2_Ref = {{ebicite|correct|EBI}}
| ChEMBL2 = 1201179
| NIAID_ChemDB      = 
| PDB_ligand        = FMM
| synonyms          = 

<!--Chemical data-->
| C=29 | H=26 | Cl=1 | F=1 | N=4 | O=4 | S=1 
| smiles = CS(=O)(=O)CCNCc1ccc(o1)c2ccc3c(c2)c(ncn3)Nc4ccc(c(c4)Cl)OCc5cccc(c5)F
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BCFGMOOMADDAQU-UHFFFAOYSA-N
}}
'''拉帕替尼'''（[[国际非专有药名|INN]]，[[諾華|諾華]]商品名'''Tykerb'''、'''Tyverb'''、'''泰嘉錠'''<ref>[https://802.mnd.gov.tw/DetailP0200155.ShowItemDetailState.do?StateEvent=GetDoseGuideEvent&MasterRecord.GroupId=ACM11111&MasterRecord.DoseGuideId=DG00002472 用藥指導 LAPATINIB]－[[國軍高雄總醫院|國軍高雄總醫院]]</ref>）是一种用于治疗乳腺癌和其他实体瘤的口服活性药物，以二甲苯磺酸拉帕替尼的形式使用。<ref>{{Cite journal |last=Burris |first=Howard A. |date=2004 |title=Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib |url=https://pubmed.ncbi.nlm.nih.gov/15163842 |journal=The Oncologist |volume=9 Suppl 3 |doi=10.1634/theoncologist.9-suppl_3-10 |issn=1083-7159 |pmid=15163842 |access-date=2022-06-13 |archive-date=2022-06-15 |archive-url=https://web.archive.org/web/20220615135632/https://pubmed.ncbi.nlm.nih.gov/15163842/ }}</ref>它是一种双酪氨酸激酶抑制剂，可中断 HER2/neu和表皮生长因子受体通路。<ref>{{Cite journal |last=Higa |first=Gerald M. |last2=Abraham |first2=Jame |date=2007-09 |title=Lapatinib in the treatment of breast cancer |url=https://pubmed.ncbi.nlm.nih.gov/17892419 |journal=Expert Review of Anticancer Therapy |volume=7 |issue=9 |doi=10.1586/14737140.7.9.1183 |issn=1744-8328 |pmid=17892419 |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613033950/https://pubmed.ncbi.nlm.nih.gov/17892419/ }}</ref>它用于 HER2 阳性乳腺癌的联合治疗。 它用于治疗肿瘤过度表达 HER 的晚期或转移性乳腺癌患者。<ref>{{Cite journal |date=2010-03 |title=Breast cancer drug approved for new indication |url=https://pubmed.ncbi.nlm.nih.gov/20187722 |journal=Women's Health (London, England) |volume=6 |issue=2 |doi=10.2217/whe.10.11 |issn=1745-5065 |pmid=20187722 |access-date=2022-06-13 |archive-date=2022-06-18 |archive-url=https://web.archive.org/web/20220618121351/https://pubmed.ncbi.nlm.nih.gov/20187722/ }}</ref>

== 作用机制 ==
拉帕替尼是小分子4-苯胺基喹唑啉类受体酪氨酸激酶抑制剂，抑制表皮生长因子受体（ErbB1）和人表皮因子受体2（ErbB2）。<ref name="drugs">{{Cite web |title=Lapatinib Uses, Side Effects & Warnings |url=https://www.drugs.com/mtm/lapatinib.html |website=Drugs.com |language=en |access-date=2022-06-13 |archive-date=2022-06-13 |archive-url=https://web.archive.org/web/20220613034126/https://www.drugs.com/mtm/lapatinib.html }}</ref>

== 不良反应 ==
拉帕替尼不良反应主要为胃肠道反应，包括恶心、腹泻、口腔炎和消化不良等，皮肤干燥、皮疹，其他有背痛、呼吸困难及失眠等。<ref name="drugs"></ref>

== 相互作用 ==
在体外拉帕替尼在治疗浓度可抑制CYP3A4和CYP2C8，并且主要由CYP3A4代谢，抑制此酶活性的药物能显著提高拉帕替尼的血药浓度。<ref name="drugs"></ref>

== 参考文献 ==
{{Reflist|4}}

== 外部链接 ==


{{GlaxoSmithKline}}
{{Extracellular chemotherapeutic agents}}

[[Category:受体酪氨酸激酶抑制剂|Category:受体酪氨酸激酶抑制剂]]
[[Category:呋喃|Category:呋喃]]
[[Category:喹唑啉|Category:喹唑啉]]
[[Category:葛兰素史克|Category:葛兰素史克]]
[[Category:有机氟化合物|Category:有机氟化合物]]
[[Category:芳香醚|Category:芳香醚]]
[[Category:有机氯化合物|Category:有机氯化合物]]
[[Category:芳香胺|Category:芳香胺]]
[[Category:胺|Category:胺]]
[[Category:砜|Category:砜]]
[[Category:苯胺|Category:苯胺]]